CL2019001354A1 - Administración intratecal de virus recombinante adeno–asociado que codifica la proteína 2 que une metilo–cpg. - Google Patents

Administración intratecal de virus recombinante adeno–asociado que codifica la proteína 2 que une metilo–cpg.

Info

Publication number
CL2019001354A1
CL2019001354A1 CL2019001354A CL2019001354A CL2019001354A1 CL 2019001354 A1 CL2019001354 A1 CL 2019001354A1 CL 2019001354 A CL2019001354 A CL 2019001354A CL 2019001354 A CL2019001354 A CL 2019001354A CL 2019001354 A1 CL2019001354 A1 CL 2019001354A1
Authority
CL
Chile
Prior art keywords
binding protein
associated virus
recombinant adeno
cpg binding
intrathecal administration
Prior art date
Application number
CL2019001354A
Other languages
English (en)
Spanish (es)
Inventor
Brian K Kaspar
Kevin Foust
Original Assignee
Nationwide Childrens Hospital Inc
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nationwide Childrens Hospital Inc, Ohio State Innovation Foundation filed Critical Nationwide Childrens Hospital Inc
Publication of CL2019001354A1 publication Critical patent/CL2019001354A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
CL2019001354A 2016-11-17 2019-05-17 Administración intratecal de virus recombinante adeno–asociado que codifica la proteína 2 que une metilo–cpg. CL2019001354A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662423618P 2016-11-17 2016-11-17

Publications (1)

Publication Number Publication Date
CL2019001354A1 true CL2019001354A1 (es) 2019-09-13

Family

ID=62145776

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001354A CL2019001354A1 (es) 2016-11-17 2019-05-17 Administración intratecal de virus recombinante adeno–asociado que codifica la proteína 2 que une metilo–cpg.

Country Status (15)

Country Link
US (3) US11583564B2 (cg-RX-API-DMAC7.html)
EP (1) EP3541429A4 (cg-RX-API-DMAC7.html)
JP (3) JP7106534B2 (cg-RX-API-DMAC7.html)
KR (1) KR102641846B1 (cg-RX-API-DMAC7.html)
CN (2) CN110325219B (cg-RX-API-DMAC7.html)
AU (2) AU2017362491B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019009834B1 (cg-RX-API-DMAC7.html)
CA (1) CA3044291A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001354A1 (cg-RX-API-DMAC7.html)
IL (2) IL322146A (cg-RX-API-DMAC7.html)
MA (1) MA46863A (cg-RX-API-DMAC7.html)
MX (1) MX2019005874A (cg-RX-API-DMAC7.html)
SA (1) SA519401806B1 (cg-RX-API-DMAC7.html)
SG (1) SG10202105090WA (cg-RX-API-DMAC7.html)
WO (1) WO2018094251A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110325219B (zh) * 2016-11-17 2024-03-26 全国儿童医院公司 编码甲基-CpG结合蛋白2的重组腺相关病毒的鞘内递送
BR112019013268A2 (pt) 2017-11-08 2019-12-17 Avexis Inc. meios e métodos para a preparação de vetores virais e usos dos mesmos
EP3801638A1 (en) 2018-06-08 2021-04-14 Novartis AG Cell-based assay for measuring drug product potency
AU2020217708A1 (en) * 2019-02-04 2021-08-19 Ohio State Innovation Foundation Adeno-associated virus delivery of CLN3 polynucleotide
WO2021077101A1 (en) * 2019-10-18 2021-04-22 Research Institute At Nationwide Children's Hospital Materials and methods for the treatment of disorders associated mutations in the irf2bpl gene
AU2020385387A1 (en) * 2019-11-22 2022-06-02 Fondazione Irccs Ca' Granda Ospedale Maggiore Foliclinico Materials and methods for treatment of disorders associated with the IGHMBP2 gene
US20240189452A1 (en) 2021-04-13 2024-06-13 Research Institute At Nationwide Children's Hospital Recombinant Adeno-Associated Virus Encoding Methyl-CPG Binding Protein 2 for Treating PITT Hopkins Syndrome VIA Intrathecal Delivery
CN121175427A (zh) * 2023-05-15 2025-12-19 上海金珂博生物技术有限公司 一种Rett综合症的基因治疗

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2176215C (en) 1993-11-09 2007-06-26 James P. Trempe Stable cell lines capable of expressing the adeno-associated virus replication gene
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
RU2273645C9 (ru) 1994-08-17 2006-11-27 Дзе Рокефеллер Юниверсити Полипептид ожирения (ов)(варианты), его аналог (варианты) и слитый белок (варианты), изолированная молекула нуклеиновой кислоты, молекула днк, рекомбинантный вектор клонирования, рекомбинантный вектор экспрессии, фармацевтическая композиция, моноклональное и поликлональное антитело
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
CA2230655C (en) 1995-08-30 2008-06-17 Genzyme Corporation Chromatographic purification of adenovirus and aav
WO1997009441A2 (en) 1995-09-08 1997-03-13 Genzyme Corporation Improved aav vectors for gene therapy
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
ES2344660T3 (es) 1996-09-06 2010-09-02 The Trustees Of The University Of Pennsylvania Uso de virus adeno-asociados recombinantes en la preparacion de un medicamento para la terapia genica mediante celulas musculares.
WO1999011764A2 (en) 1997-09-05 1999-03-11 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
GB9916702D0 (en) 1999-07-16 1999-09-15 Cantab Pharma Res Virus vectors and preparations and their use
US7056502B2 (en) 2000-04-28 2006-06-06 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
ES2526341T3 (es) 2001-12-17 2015-01-09 The Trustees Of The University Of Pennsylvania Secuencias de serotipo 9 de virus adeno-asociado (AAV), vectores que las contienen, y usos de las mismas
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
CA2554380C (en) * 2004-02-17 2015-05-19 The Hospital For Sick Children Mecp2e1 gene
LT3146982T (lt) * 2006-10-03 2019-11-11 Genzyme Corp Amiotrofinės lateralinės sklerozės ir kitų nugaros smegenų sutrikimų genų terapija
NZ586576A (en) 2008-01-15 2012-08-31 Abbott Lab Improved mammalian expression vectors and uses thereof
US20090246768A1 (en) 2008-02-15 2009-10-01 Sawalha Amr H Predicting and Diagnosing Patients With Autoimmune Disease
US9415121B2 (en) * 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
US11219696B2 (en) 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
JP6202701B2 (ja) 2014-03-21 2017-09-27 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及びプログラム
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法
WO2016100575A1 (en) * 2014-12-16 2016-06-23 Board Of Regents Of The University Of Nebraska Gene therapy for juvenile batten disease
CN110325219B (zh) * 2016-11-17 2024-03-26 全国儿童医院公司 编码甲基-CpG结合蛋白2的重组腺相关病毒的鞘内递送
EP3635122A4 (en) * 2017-06-06 2021-03-31 University of Massachusetts SELF-REGULATING AAV VECTORS FOR THE SAFE EXPRESSION OF MECP2 IN RETT SYNDROME

Also Published As

Publication number Publication date
US12357663B2 (en) 2025-07-15
BR112019009834B1 (pt) 2022-05-17
EP3541429A4 (en) 2020-08-12
SA519401806B1 (ar) 2023-03-08
CN110325219B (zh) 2024-03-26
MX2019005874A (es) 2020-02-07
AU2017362491A1 (en) 2019-06-06
SG10202105090WA (en) 2021-06-29
JP2020503265A (ja) 2020-01-30
JP7106534B2 (ja) 2022-07-26
IL266678B1 (en) 2025-08-01
AU2023202598A1 (en) 2023-07-20
CN110325219A (zh) 2019-10-11
IL266678A (en) 2019-07-31
CA3044291A1 (en) 2018-05-24
EP3541429A1 (en) 2019-09-25
US11583564B2 (en) 2023-02-21
US20230321164A1 (en) 2023-10-12
JP2022137210A (ja) 2022-09-21
IL322146A (en) 2025-09-01
JP2024045289A (ja) 2024-04-02
MA46863A (fr) 2019-09-25
RU2019118300A3 (cg-RX-API-DMAC7.html) 2021-01-11
RU2019118300A (ru) 2020-12-17
WO2018094251A1 (en) 2018-05-24
BR112019009834A2 (pt) 2019-10-08
AU2017362491B2 (en) 2023-02-02
CN118490845A (zh) 2024-08-16
US20250312400A1 (en) 2025-10-09
KR20190126047A (ko) 2019-11-08
KR102641846B1 (ko) 2024-02-27
US20200179467A1 (en) 2020-06-11
IL266678B2 (en) 2025-12-01

Similar Documents

Publication Publication Date Title
CL2019001354A1 (es) Administración intratecal de virus recombinante adeno–asociado que codifica la proteína 2 que une metilo–cpg.
CO2018013738A2 (es) Novedosos virus vaccinia modificados genéticamente
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
CY1123211T1 (el) Meθοδoi γia th θepaπeytikh antimetωπισh ή thn προληψη thς hmikpaniaς
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
CL2023001793A1 (es) Anticuerpos anti-componente de complemento y métodos de uso
CL2019000694A1 (es) Un complejo novedoso que comprende un péptido penetrante de células, una carga y un agonista de péptido de tlr para tratamiento de cáncer colorrectal.
PE20181338A1 (es) Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden
MX2016014187A (es) Adenovirus que comprende una fraccion de union a albumina.
CY1125582T1 (el) Συνθεσεις και μεθοδοι για εκλυση μακρας διαρκειας των ανταγωνιστων της εκλυτικης ορμονης των γοναδοτροπινων (gnrh).
UY37381A (es) Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
AR120096A1 (es) Vacunas para vhb y métodos de tratamiento de vhb
CL2019003430A1 (es) Tratamiento conjunto antineoplásico.
BR112018001683A2 (pt) adenovírus recombinante, composição, uso de um adenovírus ou uma composição, e, adenovírus de símio não humano.
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
MX2018005544A (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer.
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
DOP2017000236A (es) Neutralización del virus chikungunya mediada por anticuerpos
CL2021001739A1 (es) Inhibidores de la proteína de activación de fibroblastos.
CL2018002793A1 (es) Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control
UY37449A (es) Anticuerpos anti-chikv y usos de éstos
ECSP19000169A (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant
BR112017023855A2 (pt) o uso de estimulantes de sgc, ativadores de scg, em separado e combinações com inibidores de pde5 para o tratamento de úlceras digitais (du) concomitantes à esclerose múltipla (ssc)
MX381598B (es) Combinación farmacéutica que comprende un parvovirus y bevacizumab.